Application value of folate receptor-positive circulating tumor cells in auxiliary diagnosis and therapeutic effect monitoring of ovarian cancer

WANG Ying; SHEN Fujin; ZHENG Hongyun; FENG Dan

doi:10.7619/jcmp.20220206

Journal of Clinical Medicine in Practice > 2022 > 26(13): 79-83, 92. > DOI: 10.7619/jcmp.20220206

WANG Ying, SHEN Fujin, ZHENG Hongyun, FENG Dan. Application value of folate receptor-positive circulating tumor cells in auxiliary diagnosis and therapeutic effect monitoring of ovarian cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(13): 79-83, 92. DOI: 10.7619/jcmp.20220206

Citation:

PDF (729 KB)

Application value of folate receptor-positive circulating tumor cells in auxiliary diagnosis and therapeutic effect monitoring of ovarian cancer

1.
Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060
2.
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060

More Information

Received Date: January 14, 2022
Available Online: July 01, 2022

Graphical Abstract

Abstract

Abstract

Objective
To investigate the clinical application value of folate receptor-positive circulating tumor cells (FFR⁺-CTC) in the auxiliary diagnosis and curative effect monitoring of ovarian cancer.
Methods
Thirty-one patients with ovarian cancer were retrospectively selected as ovarian cancer group, and 59 healthy individuals were included in control group. The peripheral blood FR⁺-CTC contents of the two groups were compared, and the FR⁺-CTC detection results of ovarian cancer patients with different clinical characteristics were observed. The diagnosis of ovarian cancer by FR⁺-CTC, serum tumor markers including carbohydrate antigen 125 (CA125) and human epididymal protein 4 (HE4) were compared, and the staging of FR⁺-CTC and CA125 positive ovarian cancer patients were analyzed.
Results
There were no significant differences in the positive rate of FR⁺-CTC among ovarian cancer patients with different ages, different stages, different tissue types and with or without distant metastasis (P>0.05). The levels of FR⁺-CTC in peripheral blood of patients in the ovarian cancer group before and after treatment were higher than those in the control group (P < 0.05). After treatment, the level of FR⁺-CTC in peripheral blood of the ovarian cancer group was lower than before treatment, but the difference was not statistically significant (P>0.05). The sensitivity of peripheral blood FR⁺-CTC in the diagnosis of ovarian cancer was 87.10%, which was higher than 63.16% by CA125 and 52.38% by HE4, respectively, and the differences were statistically significant (χ²=3.934, 7.669, P=0.047, 0.006). FR⁺-CTC can be used as an early independent predictor of ovarian cancer. The results of Pearson correlation analysis showed that there were no correlations of FR⁺-CTC with CA125 and HE4 (r=0.280, 0.384, P>0.05). Among the patients with FR⁺-CTC positive ovarian cancer, patients in stages of Ⅲ to Ⅳ accounted for 70.37%, which was higher than 29.63% in those in stages of Ⅰ to Ⅱ, and the differences were statistically significant (P < 0.05). In CA125 positive ovarian cancer patients, the proportion of patients in stages of Ⅲ to Ⅳ was 91.67%, which was higher than 8.33% of those in stages ofⅠtoⅡ, and the difference was statistically significant (P < 0.05).
Conclusion
The content of FR⁺-CTC in peripheral blood of patients with ovarian cancer is significantly higher than healthy people, and the content of FR⁺-CTC in peripheral blood decreases after treatment, and diagnostic efficacy of FR⁺-CTC is better in diagnosis of stages of Ⅰ to Ⅱovarian cancer than CA125, suggesting that peripheral blood FR⁺-CTC can be used for early diagnosis and curative effect monitoring of ovarian cancer.
- circulating tumor cells,
- folate receptor,
- ovarian cancer,
- carbohydrate antigen 125,
- human epididymal protein 4

FullText(HTML)

References (29)

References

[1]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[2]	LI X D, WANG X P. The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer[J]. Mol Cancer, 2017, 16(1): 92. doi: 10.1186/s12943-017-0659-y
[3]	CHEN X K, GU C L, FAN J Q, et al. P-STAT3 and IL-17 in tumor tissues enhances the prognostic value of CEA and CA125 in patients with lung adenocarcinoma[J]. Biomed Pharmacother, 2020, 125: 109871. doi: 10.1016/j.biopha.2020.109871
[4]	杨玲, 周建政. 人附睾蛋白4在上皮性卵巢癌中的应用价值[J]. 临床与病理杂志, 2021, 41(3): 683-688. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB202103031.htm
[5]	景志英, 张颖. 血清D-二聚体、CA125、HE4在卵巢癌患者中的表达及诊断价值[J]. 中国卫生工程学, 2021, 20(2): 276-277. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202102038.htm
[6]	NIE L J, LI F L, HUANG X L, et al. Folic acid targeting for efficient isolation and detection of ovarian cancer CTCs from human whole blood based on two-step binding strategy[J]. ACS Appl Mater Interfaces, 2018, 10(16): 14055-14062. doi: 10.1021/acsami.8b02583
[7]	PEARL M L, DONG H, TULLEY S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)[J]. Gynecol Oncol, 2015, 137(2): 229-238. doi: 10.1016/j.ygyno.2015.03.002
[8]	LEDERMANN J A, CANEVARI S, THIGPEN T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments[J]. Ann Oncol, 2015, 26(10): 2034-2043. doi: 10.1093/annonc/mdv250
[9]	王淼, 舒博学, 王娟. 血清CA125联合PET/CT对早期卵巢癌的诊断效果[J]. 临床医学研究与实践, 2021, 6(4): 109-111. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202104039.htm
[10]	龚科, 佟秀琴, 高鑫. 卵巢癌晚期的药物治疗进展[J]. 癌症进展, 2020, 18(22): 2283-2285. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202022004.htm
[11]	WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41: 3-14. doi: 10.1016/j.bpobgyn.2016.08.006
[12]	郑红云, 付珊, 李艳. 175例卵巢肿瘤患者血清肿瘤标志物水平分析[J]. 微循环学杂志, 2019, 29(3): 45-48. doi: 10.3969/j.issn.1005-1740.2019.03.010
[13]	MOUFARRIJ S, DANDAPANI M, ARTHOFER E, et al. Epigenetic therapy for ovarian cancer: promise and progress[J]. Clin Epigenetics, 2019, 11(1): 7. doi: 10.1186/s13148-018-0602-0
[14]	刘博, 黄露, 曹亚, 等. 叶酸受体阳性CTC检测在恶性肺部结节辅助诊断中的应用[J]. 第三军医大学学报, 2020, 42(23): 2330-2335. https://www.cnki.com.cn/Article/CJFDTOTAL-DSDX202023011.htm
[15]	WEI T T, ZHU D L, YANG Y, et al. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment[J]. PLoS One, 2019, 14(7): e0219129. doi: 10.1371/journal.pone.0219129
[16]	戚丽娜, 郑树. 循环肿瘤细胞及循环肿瘤DNA检测在乳腺癌中的研究进展[J]. 中华乳腺病杂志: 电子版, 2018, 12(3): 187-190. doi: 10.3877/cma.j.issn.1674-0807.2018.03.012
[17]	潘玉婷, 范润佳, 陈诗韵, 等. 液体活检与结直肠癌: 系统综述[J]. 肿瘤综合治疗电子杂志, 2021, 7(1): 65-69. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202101013.htm
[18]	ASANTE D B, CALAPRE L, ZIMAN M, et al. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time[J]. Cancer Lett, 2020, 468: 59-71. doi: 10.1016/j.canlet.2019.10.014
[19]	KIM H, LIM M, KIM J Y, et al. Circulating tumor cells enumerated by a centrifugal microfluidic device as a predictive marker for monitoring ovarian cancer treatment: a pilot study[J]. Diagnostics, 2020, 10(4): 249. doi: 10.3390/diagnostics10040249
[20]	CHEBOUTI I, KUHLMANN J D, BUDERATH P, et al. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer[J]. Oncotarget, 2017, 8(15): 24303-24313. doi: 10.18632/oncotarget.13286
[21]	李晓利, 赵晶, 于腾阁, 等. 循环肿瘤细胞在上皮性卵巢癌诊断中的应用价值[J]. 医药论坛杂志, 2020, 41(6): 91-94, 99. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX202006024.htm
[22]	刘春华, 田艳, 道寿丽, 等. 晚期卵巢癌患者外周血循环肿瘤细胞的检测及临床意义[J]. 中国妇幼保健, 2019, 34(18): 4155-4157. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB201918014.htm
[23]	ANYS-PALUCHOWSKI M, FEHM T, NEUBAUER H, et al. Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer[J]. Arch Gynecol Obstet, 2020, 301(4): 1027-1035. doi: 10.1007/s00404-020-05477-7
[24]	BABIC A, CRAMER D W, KELEMEN L E, et al. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium[J]. Cancer Causes Control, 2017, 28(5): 459-468. doi: 10.1007/s10552-016-0841-3
[25]	邓森灵, 兰代群, 曹雅文, 等. 血清miR-222、HE4及CA125水平联合ROMA指数对上皮性卵巢癌的诊断价值[J]. 现代妇产科进展, 2021, 30(3): 189-192. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202103007.htm
[26]	CHEN L, YANG X, ABASI X, et al. The diagnostic, prediction of postoperative recurrence and prognostic value of HE4 in epithelial ovarian cancer[J]. J BUON, 2018, 23(2): 428-432.
[27]	PEARL M L, ZHAO Q, YANG J, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 134(3): 581-590. doi: 10.1016/j.ygyno.2014.06.013
[28]	ZHANG X H, LI H, YU X Y, et al. Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker[J]. Cell Physiol Biochem, 2018, 48(5): 1983-1994. doi: 10.1159/000492521
[29]	ROMERO-LAORDEN N, OLMOS D, FEHM T, et al. Circulating and disseminated tumor cells in ovarian cancer: a systematic review[J]. Gynecol Oncol, 2014, 133(3): 632-639.

Cited By

Get Citation

PDF

XML

Article views (154) PDF downloads (16)

Turn off MathJax

Article Contents

Abstract

References

Application value of folate receptor-positive circulating tumor cells in auxiliary diagnosis and therapeutic effect monitoring of ovarian cancer

Abstract

References

Catalog

Export File

Citation

Format

Content